K-pharma to participate in J.P. Morgan Healthcare Conference

Showcasing their ‘R&D achievements’

The J.P. Morgan Healthcare Conference is scheduled to take place in San Francisco, the U.S., from Jan. 8-11.

Yuhan, Hanmi, Dong-A, SK Biopharm, and others are scheduled to participate in the conference with aims to present their key pipelines and business plans

Samsung Biologics and Celltrion will present in the main track, and showcase their mid-to-long-term vision

The J.P.

 

Morgan Healthcare Conference is scheduled to take place in San Francisco, the U.S., from Jan.

 

8-11.

 

(screen captured from J.P.

 

Morgan homepage)

# Korean pharmaceutical and biotech firms are fully prepared to attend the J.P.

 

Morgan Healthcare Conference, the first international event of the year.

 

The spotlight is on what accomplishments Korean pharmaceutical and biotech firms might achieve at this event, where they will join global companies to discuss large-scale technology transfers and partnership agreements.

 

According to the pharmaceutical and biotech firms on the 4th, companies participating in the J.P.

 

Morgan Healthcare Conference include Yuhan Corporation, Hanmi Pharm, Dong-A ST, and SK Biopharmaceuticals.

 

Companies such as Samsung Biologics and Lotte Biologics, with plans to expand their contract development and manufacturing organization (CDMO) businesses, will also participate in the J.P.

 

Morgan Healthcare Conference to share their mid-to-long-term business strategy.

 

The J.P.

 

Morgan Healthcare Conference, hosted by U.S.

 

investment bank J.P.

 

Morgan, is the biopharmaceutical industry’s premier investment event that brings together global investors, including venture capital (VC) and hedge funds.

 

The event is scheduled to take place in San Francisco, the U.S., from Jan.

 

8-11.

 

Pharmaceutical industry aiming for global entry showcases R&D achievements in the New Year. Yeul-Hong Kim, R&D President of Yuhan Corporations, and Donghoon Lee, CEO of SK Biopharmaceuticals, will present in the Asia-Pacific (APA) session.

 

Yuhan Corporation

#Yuhan Corporation will showcase its key pipelines, including Leclaza (ingredient: Lazertinib), a new drug for treating non-small cell lung cancer (NSCLC).

 

Currently, Leclaza has submitted a new drug application with the U.S.

 

Food and Drug Administration (FDA) to be used in combination with Rybrevant.

 

In December of last year, Johnson & Johnson (J&J) submitted an application for its combination therapy to be used as a first-line treatment of EGFR-positive NSCLC.

 

The recent submission is based on results from the Phase 3 MARIPOSA clinical study, which tested the effectiveness of the combination therapy of Rybrevant and Leclaza compared to existing Tagrisso monotherapy.

 

Yuhan has reached an agreement with Johnson & Johnson (J&J) for the technology transfer of Leclaza following discussions in the J.P.

 

Morgan Healthcare Conference.

 

The contract was initiated in 2018, and both companies have since engaged in joint research.

 

SK Biopharmaceuticals

#SK Biopharmaceuticals will showcase its achievements with Xcopri (cenobamate), a new medication for epilepsy.

 

Xcopri achieved a monthly total prescriptions (TRx) of 22,000 in the U.S.

 

last year.

 

SK Biopharmaceuticals aims to optimize the sales performance of Xcopri in the North American market.

 

Additionally, SK Biopharmaceuticals will unveil its plan to advance in targeted protein degradation (TPD), cell and gene therapy (CGT), and radiopharmaceutical therapy (RPT) as part of its strong growth engine.

 

Hanmi Pharm

#Hanmi Pharm will showcase its entire pipelines, which includes HOP (Hanmi Obesity Pipeline).

 

Hanmi is actively conducting clinical development of Efpeglenatide, a new drug candidate designed for the treatment of obesity and non-alcoholic fatty liver disease (NAFLD).

 

The candidate drug has a multifaceted mechanism of action, activating glucagon, which increases energy metabolism, Glucagon-like peptide-1 (GLP-1), which stimulates insulin secretion and reduces appetite, and GIP receptor, which stimulates insulin secretion and promotes anti-inflammatory signaling.

 

Additionally, Hanmi’s Efinopegdutide is a dual-action treatment that simultaneously activates both the GLP-1 receptor, which helps to suppress insulin secretion and appetite, and the glucagon receptor, increasing energy metabolism.

 

Hanmi licensed out efinopegdutide to MSD in August 2020.

 

Dong-A ST

#Dong-A ST is expected to participate in the event, with representatives from its research center and business development team attending.

 

They will be focusing on strategizing agendas, networking, and exploring partnering with global pharmaceutical companies during the event Dong-A ST’s DBM-3115, a biosimilar referencing Stelara, is likely to receive European approval by next year.

 

The company has successfully completed its global Phase 3 clinical trials, demonstrating therapeutic equivalence between DBM-3115 and Stelara, and submitted its application for approval to the European Medicines Agency (EMA) in June of last year.

 

Additionally, Dong-A ST is preparing the U.S.

 

Food and Drug Administration (FDA) approval next year.

 

Through its subsidiary NeuroBo Pharmaceuticals, Dong-A ST is also developing the obesity treatment DA-1726.

 

Recently, Neurobo submitted a global Phase 1 Investigational New Drug (IND) to the U.S.

 

Food and Drug Administration (FDA) for the development of DA-1726 as an obesity treatment.

 

The preclinical research results have demonstrated that DA-1726 exhibited significant weight loss effects, even with a similar food intake to GLP-1 analog semaglutide, in animal models of obesity.

 

Samsung Biologics and Lotte Biologics to promote CDMO, and Celltrion plans to present key biosimilar pipelines.

Samsung Biologics

#Samsung Biologics will present its achievements from last year and its plans for the future in the main track on the 9th.

 

Samsung Biologics plans to establish manufacturing facilities for Antibody-Drug Conjugate (ADC) production starting this year, following its investment in Araris Biotech, a company focused on the development of ADC therapies, through the Life Sciences Fund it established with Samsung C&T in April of this year.

 

Lotte Biologics

#Lotte Biologics plans to promote its contract development and manufacturing organization (CDMO) capabilities at this conference.

 

Lotte Biologics plans to expand its ADC facility within the Syracuse factory in the United States.

 

Following this expansion, the company will offer contract services for the entire process of ADC-related pharmaceuticals, from product development to commercial production.

 

The company's strategy involves targeting both domestically developed new drug candidates and new drugs from multinational pharmaceutical companies as CDMO customers.

 

Lotte Biologics is also expressing interest in ADC.

 

In addition to last year's investment in the ADC specialist company Pino Bio, Lotte Biologics has signed a business agreement with KANAPH Therapeutics for the establishment of an ADC technology platform.

 

Celltrion

#Celltrion is set to present its key pipelines, including biosimilars, during the main track of the conference on the 10th.

 

Zymfentra received approval as a biosimilar subcutaneous (SC) product referencing Remsima inn October of the previous year.

 

Celltrion is anticipating approval for several biosimilars, including CT-P41, referencing Prolia, CT-P39, referencing Xolair, CT-P43, referencing Stelara, CT-P42, referencing Eylea.

 

These four candidate products demonstrated non-equivalence compared to the original medicine in the Phase 3 clinical trials.

 

SK Biosciences

#SK Biosciences has received officially invitations for one-on-one meetings with investors.

 

As part of its efforts to enhance the global competitiveness of its CDMO products, the company is currently establishing a global R&D center in Incheon, Songdo.

 

SK Biosciences has a mid-to-long-term plan to expand its CDMO business not only in traditional vaccine platforms but also in new platforms such as mRNA (messenger ribonucleic acid) and CGT (cell and gene therapy).

 

This strategy aims to secure new sources of growth for the company.

 

Biotech venture companies such as GI Innovation, ABL Bio, and SyntekaBio will be attending.

The J.P.

 

Morgan Healthcare Conference is scheduled to take place in San Francisco, the U.S., from Jan.

 

8-11.

 

(screen captured from J.P.

 

Morgan homepage)

0#GI Innovation will attend the conference to promote its pipelines under development.

 

GI Innovation is currently conducting the Phase 1 clinical trial of evaluating the effectiveness of the combination therapies of new drug candidate GI-101, a potential anti-cancer immune drug, and MSD’s Keytruda in the U.S.

 

The company aims to acquire indication in solid cancer, including biliary tract cancer.

 

The company is assessing the potential for commercialization of combination therapies with various anti-cancer immune drugs, including Keytruda, and is also exploring combination therapies with AstraZeneca's Imfinzi (durvalumab) and other drugs.

 

The J.P.

 

Morgan Healthcare Conference is scheduled to take place in San Francisco, the U.S., from Jan.

 

8-11.

 

(screen captured from J.P.

 

Morgan homepage)

1#ABL Bio will also participate in the event and share its achievemnets on developments of new drug candidates.

 

ABL Bio is currently developing ADC product candidates ABL201, a candidate to treat blood cancer, and ABL202, a candidate to treat solid cancer.

 

ABL Bio has achieved a successful technology transfer of ABL201 to LegoChem Biosciences, a biotech venture company.

 

Additionally, ABL202 is currently in development, incorporating LegoChem’s ADC linker technology.

 

The J.P.

 

Morgan Healthcare Conference is scheduled to take place in San Francisco, the U.S., from Jan.

 

8-11.

 

(screen captured from J.P.

 

Morgan homepage)

2#SyntekaBio will participate in BioPartnering Conference and Biotech Showcase in the J.P.

 

Morgan Healthcare Conference.

 

The company will showcase its artificial intelligence (AI)-based new drug platform, called DeepMatcher, and explore partnering opportunities with new clients.